Double Bond Pharmaceutical AB and N.N. Alexandrov National Cancer Centre of Belarus has entered into agreement about clinical use of Temodex.
DBP announced 5 december 2016 that the company started a collaboration with N. N. Alexandrov National Cancer Centre of Belarus. The main goal was to get access to skills and resources that are relevant to the development of DBP’s products including Temodex that is a drug against brain cancer. The cooperation has been now further developed through a partnership agreement concerning a follow-up of patients with brain tumors treated in Belarus in N. N. Alexandrov National Centre, which will accelerate the process of making Temodex commercially viable worldwide. Under the agreement, all
